Hospitals

Cleveland Clinic researcher gets $720K grant to study chronic kidney disease

A Cleveland Clinic researcher has been awarded a $720,000 federal grant to test two approaches to improving chronic kidney disease care and outcomes. Dr. Joseph Nally Jr., director of the Clinic’s Center for Chronic Kidney Disease, received the three-year grant from the National Institutes of Health, according to a statement from the Clinic. “Current treatments […]

A Cleveland Clinic researcher has been awarded a $720,000 federal grant to test two approaches to improving chronic kidney disease care and outcomes.

Dr. Joseph Nally Jr., director of the Clinic’s Center for Chronic Kidney Disease, received the three-year grant from the National Institutes of Health, according to a statement from the Clinic.

“Current treatments are effective in slowing the progression of chronic kidney disease, but inadequate awareness among patients and providers has limited the widespread application of these treatments,” Nally said.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

The first clinical trial in the study will pair patients with nonclinical professionals who are trained to identify issues and barriers during the care process — such as insurance or transportation to appointments.

The second will test enhancements to electronic health records designed to assist healthcare providers in identifying and following patients who show signs of deteriorating kidney function.

Diabetes and high blood pressure are the two most common causes of chronic kidney disease and account for most cases.